Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer
| Autor: | Kimberly Schaff, Hagen F. Kennecke, Caroline Speers, Winson Y. Cheung, Leo Chen, C. D. Blanke |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Oncology
medicine.medical_specialty Combination therapy Colorectal cancer medicine.disease_cause survival mcrc Internal medicine cetuximab medicine Chemotherapy Panitumumab anti-egfr neoplasms irinotecan Performance status Cetuximab business.industry Hazard ratio medicine.disease digestive system diseases Surgery Irinotecan multivariate analysis Original Article KRAS panitumumab business medicine.drug |
| Zdroj: | Current Oncology Volume 20 Issue 6 Pages 1600-332 |
| Popis: | The survival benefit for single-agent anti&ndash epidermal growth factor receptor (egfr) therapy compared with combination therapy with irinotecan in KRAS wildtype (wt) metastatic colorectal cancer (mcrc) patients in the third-line treatment setting is not known. The objective of the present study was to describe the characteristics of, and to compare survival outcomes in, two cohorts of patients treated with either singleagent panitumumab or combination therapy with cetuximab and irinotecan. The study enrolled patients with KRAS wt mcrc previously treated with both irinotecan and oxaliplatin who had received either panitumumab or combination cetuximab&ndash irinotecan before April 1, 2011, at the BC Cancer Agency (bcca). Patients were excluded if they had received anti-egfr agents in earlier lines of therapy. Data were prospectively collected, except for performance status (ps), which was determined by chart review. Information about systemic therapy was extracted from the bcca Pharmacy Database. Of 178 eligible patients, 141 received panitumumab, and 37 received cetuximab&ndash irinotecan. Compared with patients treated with cetuximab&ndash irinotecan, panitumumab-treated patients were significantly older and more likely to have an Eastern Cooperative Oncology Group (ecog) ps of 2 or 3 (27.7% vs. 2.7%, p = 0.001). Other baseline prognostic variables and prior and subsequent therapies were similar. Median overall survival was 7.7 months for the panitumumab group and 8.3 months for the cetuximab&ndash irinotecan group. Multivariate analysis demonstrated that survival outcomes were similar regardless of the therapy selected (hazard ratio: 1.28 p = 0.34). An ecog ps of 2 or 3 compared with 0 or 1 was the only significant prognostic factor in this treatment setting (hazard ratio: 3.37 p < 0.01). Single-agent panitumumab and cetuximab&ndash irinotecan are both reasonable third-line treatment options, with similar outcomes, for patients with chemoresistant mcrc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|